Thus, THCV’s impact on systemic glucose clearance and how this influence can supplement that of SGLT2 inhibitors by relieving the burden of systemic hyperglycemia on SGLT2 activity remain important topics to explore. This evidence concerns the gene SLC5A2 and Hyperglycemia.